Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy

Journal of Infectious Diseases

Volumn 213, Issue 6, 2016, Pages 1008-1012

  Morón López, Sara ^a   Gómez Mora, Elisabet ^a   Salgado, Maria ^a   Ouchi, Dan ^a   Puertas, Maria C ^a   Urrea, Víctor ^a   Navarro, Jordi ^c   Jou, Antoni ^b   Pérez, Mercedes ^c   Tural, Cristina ^b   Clotet, Bonaventura ^a,b,e   Montaner, Luis J ^f   Blanco, Julià ^a,e   Crespo, Manuel ^c   Martinez Picado, Javier ^a,d,e  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Fundació Lluita Contra la SIDA ^*  (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^f WISTAR INSTITUTE   (United States)

Author keywords

CD4+ T cell subpopulations; HIV persistence; HIV RNA expression; HIV HCV coinfection; IFN alfa; immune activation; Siglec 1; TRIM22

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; APOBEC3G GENE; ARTICLE; BST2 GENE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; MALE; MIXED INFECTION; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT COURSE THERAPY; T LYMPHOCYTE ACTIVATION; TRIM22 GENE; TRIM5A GENE; UPREGULATION; VIRUS EXPRESSION; VIRUS GENE; VIRUS REPLICATION; CLASSIFICATION; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEPACIVIRUS; HIV INFECTIONS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PHYSIOLOGY;

ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84964842265     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv521     Document Type: Article

References (15)

1. Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381:2109-17.
2. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/. Accessed 20 September 2015.
3. Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013; 207:213-22.
4. Sun H, Buzon MJ, Shaw A, et al. Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C viruscoinfected patients. J Infect Dis 2014; 209:1315-20.
5. Jiao Y-M, Weng W-J, Gao Q-S, et al. Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. Antiviral Res 2015; 118:118-22.
6. Izquierdo-Useros N, Lorizate M, McLaren PJ, Telenti A, Kräusslich H-G, Martinez-Picado J. HIV-1 capture and transmission by dendritic cells: the role of viral glycolipids and the cellular receptor Siglec-1. PLoS Pathog 2014; 10:e1004146.
7. Puertas MC, Salgado M, Morón-López S, et al. Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. AIDS 2014; 28:2157-9.
8. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.
9. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994; 32:732-9.
10. Martínez-Bonet M, Puertas MC, Fortuny C, et al. Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. Clin Infect Dis 2015; 61:1169-78.
11. Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-5.
12. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
13. Cheadle C, Fan J, Cho-Chung YS, et al. Control of gene expression during T cell activation: alternate regulation of mRNA transcription and mRNA stability. BMC Genomics 2005; 6:75.
14. Massanella M, Tural C, Papagno L, et al. Changes in T-cell subsets in HIV-HCVcoinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antivir Ther 2010; 15:333-42.
15. Singh R, Gaiha G, Werner L, et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol 2011; 85:208-16.